• 1. The products, kinetics, and mechanisms of metal ion-promoted hydrolyses of thioimidate esters and the effects of hydrogen ions on thioimidate ester hydrolyses
  Alan J. Hall,Derek P. N. Satchell J. Chem. Soc. Perkin Trans. 2 1976 1274
• 2. Reaction of phosphorus-stabilized carbanions with cyclic enones. Aromatization of the substitution and addition products
  Malose J. Mphahlele,André Pienaar,Tomasz A. Modro J. Chem. Soc. Perkin Trans. 2 1996 1455

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Ergoline and derivatives Lysergamides
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Ergoline and derivatives Lysergic acids and derivatives Lysergamides

Methysergide Maleate (CAS No. 129-49-7): A Comprehensive Overview of Its Pharmacological Profile and Recent Research Applications

Methysergide Maleate, chemically designated as (1α,2α,6α,8αβ)-Octahydro-6-methyl-2,3-epoxy-2,6-dihydroxy-4-propylindol-4-one maleate (1:1) and identified by its CAS No. 129-49-7, is a well-documented compound with a rich history in pharmacological research. This synthetic derivative of ergotamine has garnered significant attention due to its unique pharmacological properties and its historical role in the management of certain medical conditions.

The compound's molecular structure, featuring a complex indole ring system with hydroxyl and propyl substituents, contributes to its potent pharmacological effects. Methysergide Maleate is primarily known for its serotonin receptor antagonist activity, particularly at the 5-HT1D and 5-HT2 receptor subtypes. This property has made it a valuable tool in the treatment of conditions associated with serotonin receptor activation, such as migraine headaches and cluster headaches.

Historically, Methysergide Maleate was widely used for its ability to prevent migraines by inhibiting the vasoconstrictive effects of serotonin on cranial blood vessels. However, its use has been associated with certain side effects, including gastrointestinal disturbances and potential cardiovascular issues, which have led to a more cautious approach in its clinical application. Despite these concerns, ongoing research continues to explore its potential benefits in other therapeutic areas.

Recent studies have delved into the compound's mechanism of action beyond its primary serotonin receptor antagonism. Research indicates that Methysergide Maleate may also exhibit dopaminergic properties, which could contribute to its efficacy in treating certain neurological disorders. Additionally, investigations into its potential role in neuroprotection have emerged, suggesting that it might have applications in the management of neurodegenerative diseases.

The pharmacokinetic profile of Methysergide Maleate has been extensively studied to optimize its therapeutic use. Its maleate salt form enhances solubility and bioavailability, making it more effective when administered orally. Clinical trials have demonstrated that Methysergide Maleate can be administered in low doses to achieve therapeutic effects while minimizing adverse reactions. This dosing strategy is crucial in managing the risks associated with long-term use.

One of the most notable recent advancements in the study of Methysergide Maleate involves its potential application in oncology research. Preliminary studies suggest that the compound may inhibit the growth of certain cancer cell lines by interfering with serotonin signaling pathways that are often dysregulated in tumors. This finding opens up new avenues for further investigation into its oncological potential.

Furthermore, the compound's ability to cross the blood-brain barrier has prompted research into its use as a scaffold for developing new central nervous system (CNS) drugs. By leveraging its unique structural features, scientists are exploring ways to modify Methysergide Maleate to enhance its selectivity and reduce side effects. These efforts aim to harness its pharmacological properties while mitigating the risks associated with traditional use.

The synthesis and characterization of Methysergide Maleate have also seen significant advancements due to improvements in chemical methodologies. Modern synthetic techniques allow for higher purity and yield, ensuring that pharmaceutical-grade material is available for clinical and experimental use. These advancements are crucial for supporting ongoing research and developing new derivatives with improved therapeutic profiles.

In conclusion, Methysergide Maleate (CAS No. 129-49-7) remains a compound of great interest in pharmaceutical research due to its multifaceted pharmacological actions and potential applications across various therapeutic areas. While historical concerns regarding its side effects have influenced clinical practice, recent discoveries continue to highlight its value as a pharmacological tool. Continued research efforts are essential to fully elucidate its mechanisms of action and explore new therapeutic possibilities.

• 57432-61-8(Methylergometrine maleate)
• 129-51-1(Ergonovine maleate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)